AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03396926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT03396926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT03396926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03396926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT00574444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transvaginal diagnostic peritoneoscopy
Description: For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
Study NCT00880880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-PAQ-PF
Description: Participants will fill out the e-PAQ-PF prior to their clinic visit. The e-PAQ-PF has 4 dimensions (urinary, bowel, vaginal, sexual) and asks about symptoms severity, bother of symptoms, and impact on quality of life. A copy of the results will be given to their clinician and the participant.
Study NCT00014911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet Transplantation
Description: Participants will receive portal vein islet infusions (up to 3), e.g., islet transplantations, with a targeted total of exceeding 10,000 islet equivalents per kilogram of body weight (IE/kg) per infusion. Up to three transplants are possible depending on individual results.
Study NCT00014911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.
Study NCT03906162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Base intervention
Description: The base intervention consists of a physical activity monitor (PAM) for everyday use in the intervention period and a pamphlet with information about Danish recommendations on physical activity in aging populations. The PAM will be the Garmin Vivofit 3 monitor linked to a pre-specified Garmin Connect account. The participants will be asked to install the Garmin Connect application on their smartphone and use the given ID/password in the app. The participants will be asked to wear the monitor 24-hours a day for the 12-week intervention period. The participants can use the PAM as they like but they will be asked to try to use the PAM and the application to enhance their daily level of physical activity.
Study NCT03906162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Base intervention
Description: The base intervention consists of a physical activity monitor (PAM) for everyday use in the intervention period and a pamphlet with information about Danish recommendations on physical activity in aging populations. The PAM will be the Garmin Vivofit 3 monitor linked to a pre-specified Garmin Connect account. The participants will be asked to install the Garmin Connect application on their smartphone and use the given ID/password in the app. The participants will be asked to wear the monitor 24-hours a day for the 12-week intervention period. The participants can use the PAM as they like but they will be asked to try to use the PAM and the application to enhance their daily level of physical activity.
Study NCT02963311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PCSSC
Description: ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.
Study NCT00014911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation. Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.
Study NCT00014911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks). Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
Study NCT02963311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.
Study NCT02902783 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Data collection relevant to this study will be obtained by observation and review of hospital charts. Limited data will be obtained through relevant organ donation organizations (ODOs).
Study NCT00014911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole
Description: An antibacterial used to prevent opportunistic infections
Study NCT03829696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifeprex® (Mifepristone 200 mg)
Description: Participants will receive Mifeprex® (mifepristone 800 mcg) from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period and would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
Study NCT03829696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 mcg
Description: Participants will receive misoprostol from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
Study NCT03829696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ella® (ulipristal acetate emergency contraception 30 mg)
Description: Participants will receive one dose of ella (emergency contraception) from a clinician at the same time of receiving mifepristone and misoprostol, in case the participant should have unprotected intercourse or failed contraception and want to prevent unintended pregnancy.
Study NCT03829696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AccuHome® Pregnancy OTC Test
Description: Participants will receive 6 AccuHome® pregnancy tests, which are midstream urine pregnancy tests and provide results within 3 minutes. Participants may request additional tests to be mailed to them by the study at any time.
Study NCT01195103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol disodium
Description: 10 mg/kg bolus
Study NCT01195103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fospropofol disodium
Description: 6.5 mg/kg bolus
Study NCT01195103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Midazolam
Description: Placebo bolus plus midazolam. The dose of midazolam will be based on the patient's weight: 1 mg for patients \<60 kg; 1.5 mg for patients ≥60 kg to \<90 kg; or 2 mg for patients ≥90 kg
Study NCT04286152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 MG
Description: The experimental drug is administered to patients PO once a day for 7 days from stent insertion until removal
Study NCT04286152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: A sugar pill manufactured to mimic Mirabegron 50 mg tablet is administered to patients PO once a day for 7 days from stent insertion until removal
Study NCT00355030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 0.05 mg/kg/day
Study NCT00355030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprorelin
Description: 11.25 mg/3 months
Study NCT02343848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart bracelet.
Description: Physical activity will be evaluated using smart bracelet.
Study NCT02415088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: block of the plexus brachialis in the interscalene region with local anaesthetics
Study NCT01602263 — intervention group
Intervention type: PROCEDURE
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Anodal, Cathodal or Sham tDCS.
Study NCT01462929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Dosage form: Dry powder. Route of administration: Oral inhalation by Genuair multidose dry powder inhaler Dose and regimen: 1 puff of 400 micrograms in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
Study NCT01462929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Dosage form: Dry powder hard gelatin capsule. Route of administration: Oral inhalation by HandiHaler single-dose dry powder inhaler Dose and regimen: 1 capsule (18 μg) in the morning (09:00 ± 1h)
Study NCT01462929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
Study NCT01673776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulsioFlex® Monitoring
Description: * goal directed therapy according to PulsioFlex® Monitoring- measurements~* femoral catheter~* extended perioperative monitoring~* nutritional supplementation, (if necessary)
Study NCT04032886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio tape
Description: This is a taping method used for correction of rounded shoulders.
Study NCT04032886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Exercises include basic postural exercises.
Study NCT04032886 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: Exercises include basic postural exercises.
Study NCT01195103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients \<60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
Study NCT01195103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients \<60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
Study NCT02536326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LEPU Renal Denervation System
Description: LEPU Renal denervation system was similar to Symplicity Catheter System (Medtronic Inc.)
Study NCT01612026 — intervention group
Intervention type: PROCEDURE
Intervention: arterial cannulation by angiographic imaging
Description: comparing successful arterial cannulation in case of non-cardiac vascular patient population.
Study NCT01024686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p52-/p36- GAP Vaccine
Description: Administered by five bites from GAP-infected Anopheles mosquito
Study NCT01024686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p52-p36- GAP Vaccine
Description: Administered by 200 bites from GAP-infected Anopeles mosquito
Study NCT01024686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p52-/p36- GAP Vaccine
Description: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
Study NCT04614623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AHCL pump
Description: Advanced Hybrid Closed Loop (AHCL) pump automatically adjusts insulin infusion rate of pump customized to patient's needs to reduce occurrence of hypo and hyperglycemia
Study NCT04614623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video conferencing Application
Description: Video conferencing application will be used to enhance communication between participant and parent with the study certified diabetes educator (CDE) nurse coordinator. These individualized sessions will be designed to help the family with solving diabetes management problems to enhance glycemic control
Study NCT01220297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Immunosuppressant administered orally to:~* Adults (age 14 and older), beginning on Day -3 with 12 mg loading dose, followed by 4 mg/day.~* Children \< 13 years or weighing 40 kg, beginning on Day -3 with 3 mg/m² loading dose, followed by 1 mg/ m², rounded to the nearest full milligram.~Daily dosage may be adjusted to maintain a target serum trough level of 3 to 12 ng/ml. Sirolimus dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
Study NCT01220297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: Immunosuppressant given intravenously (IV) at 15 mg/kg 3 times daily, starting on Day 0 ≥ 2 hr after the completion of the HSCT infusion. Dose of MMF will be based on actual body weight, but limited to 15 kg above ideal body weight. MMF dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
Study NCT01220297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -6 at the lesser of 15 mg/kg or 550 mg/m².
Study NCT01220297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -4 at 60 mg/kg
Study NCT01220297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cyclo, CY)
Description: Cyclophosphamide is a chemotherapy agent.~For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg.~For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg
Study NCT01220297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTBI
Description: For FTBI + Cyclophosphamide cohort, administered as 1320 cGy delivered in 11 120 cGy fractions over 4 days starting on Day -7.
Study NCT00361335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: 2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes
Study NCT00361335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
Study NCT00361335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
Study NCT00361335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
Study NCT03449849 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Base Diet
Description: Base Diet
Study NCT02914119 — intervention group
Intervention type: DRUG
Intervention: Rocuronium
Study NCT02914119 — intervention group
Intervention type: DRUG
Intervention: Succinylcholine
Study NCT02914119 — intervention group
Intervention type: DRUG
Intervention: Cisatracurium
Study NCT02914119 — intervention group
Intervention type: DRUG
Intervention: Mivacurium
Study NCT02914119 — intervention group
Intervention type: DEVICE
Intervention: Objective neuromuscular monitoring (acceleromyography)
Study NCT02914119 — intervention group
Intervention type: DRUG
Intervention: Sugammadex
Study NCT02914119 — intervention group
Intervention type: DRUG
Intervention: Neostigmine
Study NCT03449849 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Kale Treatment
Description: Base Diet plus Kale
Study NCT02515344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing a list of patients not compliant with CRC sreening
Description: GPs allocated to the intervention group (A) will receive a list of the patients who are not compliant to colorectal cancer screening, while GPs allocated to the others groups will not receive this information.
Study NCT02515344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing general information about CRC sreening
Study NCT02515344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Providing general information about CRC sreening
Study NCT02895516 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vibrating capsule
Description: Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
Study NCT00014911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: An antiviral used to kill viruses and stop viral replication
Study NCT00014911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim
Description: An antibacterial used to prevent opportunistic infections
Study NCT00014911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentamidine
Description: An antiprotozoal used to prevent disease
Study NCT03336190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: avatar-based training
Description: Interaction with an avatar-based module to practice skills learned during the toolkit training
Study NCT02675725 — intervention group
Intervention type: DEVICE
Intervention: Measurement of sublingual microcirculation with Cytocam-IDF camera
Description: The normal treatment of a post-cardiac surgery patient is fluid bolus by indication. This indications are hypotension, hyperlactataemia, tachycardia or decreased urine production. This fluid bolus is 250 ml crystalloids in 15 minutes.~When this fluid bolus will be given, the investigators will observe the sublingual microcirculation and measure the red blood cell velocity and total vessel density on one spot for 20 minutes.
Study NCT01057134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera Ultrasound Device
Description: Pulse duration 10-100 ms, fluence greater or equal to 50 J/cm2, contact tip temperature 5-30 celsus, frequency 5-20 MHz.
Study NCT01962688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handheld ultrasound
Description: Handheld ultrasound determination of IVC diameter
Study NCT04230967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulation Group
Description: Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit Inspire devices will be set to this goal and notifications will be given on the device for the participants meeting their goals
Study NCT04230967 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: No encouragement to ambulate will be provided to subjects. Their movement will be recorded
Study NCT02377024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TF 600mg
Study NCT02377024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TF 1200mg
Study NCT02377024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01962688 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ultrasound
Description: sham ultrasound to facilitate blinding
Study NCT02882737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon before exercise
Study NCT02882737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon after exercise
Study NCT02882737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon after resting
Study NCT01231607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1mg Finasteride active
Description: 1mg finasteride active, by mouth once daily
Study NCT01231607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.02mg dutasteride
Description: 0.02mg dutasteride active, by mouth once daily
Study NCT01231607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1mg dutasteride
Description: 0.1mg dutasteride active, by mouth once daily
Study NCT01231607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg dutasteride
Description: 0.5mg dutasteride active, by mouth once daily
Study NCT01231607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride placebo
Description: finasteride placebo, by mouth once daily
Study NCT00361335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
Study NCT00536263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha-2b
Description: 1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks
Study NCT00536263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2b
Description: 1.5 mcg/kg S.C. QW for 24 weeks